Skip to main content
Monday, November 16, 2026Nov 16

FDA wants heartburn meds off the market due to contamination

FILE - This Aug. 29, 2018, file photo shows an arrangement of Oxycodone pills in New York. A new study shoots down the notion that medical marijuana laws can prevent opioid overdose deaths. Chelsea Shover of Stanford University School of Medicine and colleagues reported the findings Monday, June 10, in Proceedings of the National Academy of Sciences. (AP Photo/Mark Lennihan, File)
FILE - This Aug. 29, 2018, file photo shows an arrangement of Oxycodone pills in New York. A new study shoots down the notion that medical marijuana laws can prevent opioid overdose deaths. Chelsea Shover of Stanford University School of Medicine and colleagues reported the findings Monday, June 10, in Proceedings of the National Academy of Sciences. (AP Photo/Mark Lennihan, File)

WASHINGTON (AP) – U.S. health regulators are telling drugmakers to immediately pull their popular heartburn drugs off the market after determining that a contamination issue with the medications poses a greater risk than previously thought.

The move from the Food and Drug Administration Wednesday applies to all prescription and over-the-counter versions of ranitidine, best known by the brand name Zantac. The drugs are widely used to treat stomach acid and ulcers.

Patients should stop taking any of the medications they currently have and throw them away, the FDA said.

The agency last year said patients could continue taking the medications and did not face health risks from contamination with a “probable” cancer-causing chemical found in multiple brands.

But officials reversed that decision, saying they’ve now determined that levels of the chemical increase over time, especially if tablets and capsules are stored at higher temperatures. That poses an unacceptable risk to patients, they said.